Given that current patients stratification models are focusing mostly on the amount of tumor infiltrating CD8+ T cells, results of our study provide strong rationale for including spatial relation between myeloid and T cells into CRC tumor immune-based classifications. The gene discussed is CD8A; the disease is neoplasm.